%0 Journal Article
%A Huber, Hanna
%A Arranz, Javier
%A Arslan, Burak
%A Leuzy, Antoine
%A Kittel, Oscar
%A di Molfetta, Guglielmo
%A Benejam, Bessy
%A Videla, Laura
%A Barroeta, Isabel
%A Soriano, Laura Del Hoyo
%A Maure-Blesa, Lucía
%A Rodríguez-Baz, Íñigo
%A Arriola Infante, José Enrique
%A Illán-Gala, Ignacio
%A Bejanin, Alexandre
%A Montoliu-Gaya, Laia
%A Lleó, Alberto
%A Carmona-Iragui, María
%A Alcolea, Daniel
%A Blennow, Kaj
%A Zetterberg, Henrik
%A Fortea, Juan
%A Ashton, Nicholas J
%T Plasma p-tau217 as a biomarker of Alzheimer's disease pathology in individuals with Down syndrome.
%J Nature Communications
%V 16
%N 1
%@ 2041-1723
%C [London]
%I Springer Nature
%M DZNE-2025-01255
%P 9900
%D 2025
%X Diagnosing Alzheimer's disease (AD) in adults with Down syndrome (DS), a population with a high genetically determined risk of AD, remains challenging. In this large observational study including n = 2329 samples from the Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) and euploid controls from the Sant Pau Initiative on Neurodegeneration (SPIN) with and without symptomatic AD, we investigate if the strong diagnostic performance of plasma p-tau217 observed in sporadic AD extends to the DS population. Plasma p-tau217 discriminated cognitively stable individuals with DS from those with AD dementia with an AUC of 0.96 (95
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41213934
%R 10.1038/s41467-025-65882-x
%U https://pub.dzne.de/record/281913